ClinicalTrials.gg
CompletedNCT02430311Updated Jul 31, 2019Results posted

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

A Phase 1 interventional study of Olaparib and Paclitaxel in Advanced Solid Tumours, sponsored by AstraZeneca. Completed at 3 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours. Part A will assess the single and multiple dose pharmacokinetics of olaparib monotherapy and multiple dose pharmacokinetics of olaparib in combination with paclitaxel. Part B will assess the safety of multiple doses of olaparib in Cohort 1 and of olaparib when co-administered with paclitaxel in Cohort 2

Read the detailed description

Part A will access the pharmacokinetics of olaparib: Cohort 1 will investigate the single and multiple dose pharmacokinetics of olaparib following 300mg bd monotherapy dose(s); Cohort 2 will investigate the single and multiple dose pharmacokinetics of olaparib following 100mg bd monotherapy dose(s) and the multiple dose pharmacokinetics in the presence of co-administered paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle).

In Part B: Safety profile of olaparib 300mg bd as monotherapy and olaparib 100mg bd in combination with weekly paclitaxel will also be investigated in Chinese patients.

02

Conditions studied

  • Advanced Solid Tumours

Keywords

  • Chinese Patients
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of fully
  2. Patient aged ≥ 18 years
  3. Histologically or, where appropriate, confirmed malignant solid tumour or resistant to standard therapy and for which no suitable effective standard therapy exists
  4. of ≥ 12 weeks
  5. Patients for Cohort 2 must be eligible for paclitaxel treatment
  6. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
  7. performance status ≤ 2
  8. Satisfactory organ and bone marrow function measured within 28 days prior to administration of study treatment including - ≥ 10.0 g/dL and no blood transfusion in the 4 weeks prior to the first dosing of study drug. - ≥ 1.5 × 109/L
  9. Evidence of non-childbearing status for women of , or status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1.
  10. Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and , which should be stable for at least 4 weeks prior to start of olaparib dosing.

Exclusion criteria

Exclusion criteria:

  1. Involvement in the planning and/or conduct of the study.
  2. Previous enrolment in the present study.
  3. Treatment with any product during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
  4. Any previous treatment with a Poly (ADP-ribose) polymerase (PARP) inhibitor, including olaparib.
  5. Patients with other within the last 5 years, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, ductal carcinoma in situ, Stage 1, Grade 1 endometrial cancer, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
  6. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. These include patients with gastric or intestinal cancer or patients with prior surgical procedures such as full or partial gastrectomy.
  7. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study treatment.
  8. Concomitant use of known potent (Cytochrome P450 3A4) inhibitors.
  9. Patients with any ongoing toxicities (> (Common Terminology Criteria for Adverse Events) grade 2), with the exception of alopecia, caused by previous cancer therapy.
  10. Resting with (Heart Rate Corrected QT interval) > 470msec or family history of long QT syndrome.
  11. Patients with interstitial pneumonia or diffused symptomatic fibrosis of the lungs.
  12. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  13. Patients with symptomatic uncontrolled .
  14. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  15. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  16. patients, e.g. patients who are known to be serologically positive for (HIV).
  17. Patients with known active hepatic disease (i.e. or C).
  18. Patients with a known to olaparib, paclitaxel or any of the of the product.
  19. Breastfeeding women.
  20. Clinical judgement by the investigator that the patient should not participate in the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day

    Drug: Olaparib

  • Experimental
    Cohort 2

    Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)

    Drug: Paclitaxel · Drug: Olaparib

Interventions

06

What researchers measure

Primary outcomes

  1. Single Dose PK Parameter--Cmax

    Single dose PK parameter summary for olaparib in monotherapy by dose - Cmax (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  2. Single Dose PK Parameter--AUC

    Single dose PK parameter summary for olaparib in monotherapy by dose - AUC (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  3. Single Dose PK Parameter--tmax

    Single dose PK parameter summary for olaparib in monotherapy by dose - tmax (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  4. Single Dose PK Parameter--t1/2, λz

    Single dose PK parameter summary for olaparib in monotherapy by dose - t1/2, λz (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  5. Single Dose PK Parameter--Vz/F

    Single dose PK parameter summary for olaparib in monotherapy by dose - Vz/F (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  6. Single Dose PK Parameter--CL/F

    Single dose PK parameter summary for olaparib in monotherapy by dose - CL/F (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)

  7. Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 8

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8

  8. Steady State PK Parameter--AUCss at Day 8

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8

  9. Steady State PK Parameter--tmax, ss at Day 8

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8

  10. Steady State PK Parameter--RAC and TCP at Day 8

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - RAC and TCP (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8

  11. Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 9

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)

    Time frame: PK samples were collected pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9

  12. Steady State PK Parameter--AUCss at Day 9

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9

  13. Steady State PK Parameter--tmax, ss at Day 9

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9

  14. Steady State PK Parameter--CLss/F at Day 8

    Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - CLss/F (PK analysis set)

    Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8

07

Results

Posted Sep 13, 2018

Participant flow

This study was performed at 3 study centres in China.The first patient entered the study on 10 June 2015 and the last patient completed Part A of the study on 02 August 2016, and the date of last patient last visit in Part B was 28 April 2017.

Part A
Participant flow — Part A
MilestoneCohort 1Cohort 2
Started2016
Received olaparib2016
Received paclitaxel016
Completed1915
Not completed11
Withdrew: Adverse event01
Withdrew: Withdrawal by subject10
Part B
Participant flow — Part B
MilestoneCohort 1Cohort 2
Started1915
Received olaparib1915
Received paclitaxel014
Completed97
Not completed108
Withdrew: Meet study-specific withdrawal criteria66
Withdrew: Withdrawal by subject22
Withdrew: Adverse event10
Withdrew: Death10

Outcome measures

PrimarySingle Dose PK Parameter--Cmax

Single dose PK parameter summary for olaparib in monotherapy by dose - Cmax (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Geometric mean · µg/mL
Single Dose PK Parameter--Cmax
µg/mLCohort 1Cohort 2
Single Dose PK Parameter--Cmax6.875 ± 39.702.972 ± 41.80
PrimarySingle Dose PK Parameter--AUC

Single dose PK parameter summary for olaparib in monotherapy by dose - AUC (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Geometric mean · µg*h/mL
Single Dose PK Parameter--AUC
µg*h/mLCohort 1Cohort 2
AUC0-1231.68 ± 52.9710.86 ± 61.60
AUC0-t36.37 ± 59.5812.63 ± 75.42
AUC36.53 ± 59.8612.75 ± 76.70
PrimarySingle Dose PK Parameter--tmax

Single dose PK parameter summary for olaparib in monotherapy by dose - tmax (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Median · hour
Single Dose PK Parameter--tmax
hourCohort 2Cohort 1
Single Dose PK Parameter--tmax1.95 ± 61.601.50 (0.50 to 4.00)
PrimarySingle Dose PK Parameter--t1/2, λz

Single dose PK parameter summary for olaparib in monotherapy by dose - t1/2, λz (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Mean · hour
Single Dose PK Parameter--t1/2, λz
hourCohort 2Cohort 1
Single Dose PK Parameter--t1/2, λz7.165 ± 2.5426.519 ± 1.346
PrimarySingle Dose PK Parameter--Vz/F

Single dose PK parameter summary for olaparib in monotherapy by dose - Vz/F (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Mean · L
Single Dose PK Parameter--Vz/F
LCohort 2Cohort 1
Single Dose PK Parameter--Vz/F88.32 ± 44.0474.78 ± 75.41
PrimarySingle Dose PK Parameter--CL/F

Single dose PK parameter summary for olaparib in monotherapy by dose - CL/F (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Reported as:
Mean · L/h
Single Dose PK Parameter--CL/F
L/hCohort 2Cohort 1
Single Dose PK Parameter--CL/F9.217 ± 4.5318.107 ± 6.689
PrimarySteady State PK Parameter--Cmax, ss and Cmin, ss at Day 8

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Reported as:
Geometric mean · µg/mL
Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 8
µg/mLCohort 1Cohort 2 (Olaparib Alone)
Cmax, ss8.268 ± 35.023.752 ± 40.99
Cmin, ss0.7996 ± 117.80.3162 ± 129.4
PrimarySteady State PK Parameter--AUCss at Day 8

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Reported as:
Geometric mean · µg*h/mL
Steady State PK Parameter--AUCss at Day 8
µg*h/mLCohort 1Cohort 2, Olaparib Alone
AUCss43.95 ± 48.4316.73 ± 61.38
AUC0-t43.91 ± 48.4716.68 ± 61.30
PrimarySteady State PK Parameter--tmax, ss at Day 8

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Reported as:
Median · hour
Steady State PK Parameter--tmax, ss at Day 8
hourCohort 1Cohort 2, Olaparib Alone
Steady State PK Parameter--tmax, ss at Day 81.50 (0.97 to 3.00)2.00 (0.97 to 4.02)
PrimarySteady State PK Parameter--RAC and TCP at Day 8

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - RAC and TCP (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Reported as:
Mean · Ratio
Steady State PK Parameter--RAC and TCP at Day 8
RatioCohort 1Cohort 2, Olaparib Alone
RAC1.436 ± 0.20811.565 ± 0.2984
TCP1.253 ± 0.21501.349 ± 0.3349
PrimarySteady State PK Parameter--Cmax, ss and Cmin, ss at Day 9

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)

Time frame:
PK samples were collected pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Reported as:
Geometric mean · µg/mL
Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 9
µg/mLCohort 2(Olaparib 100 mg + Paclitaxel)
Cmax, ss3.031 ± 56.14
Cmin, ss0.1915 ± 125.2
PrimarySteady State PK Parameter--AUCss at Day 9

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Reported as:
Geometric mean · µg*h/mL
Steady State PK Parameter--AUCss at Day 9
µg*h/mLCohort 2(Olaparib 100 mg + Paclitaxel)
AUCss12.44 ± 57.46
AUC0-t12.42 ± 57.36
PrimarySteady State PK Parameter--tmax, ss at Day 9

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Reported as:
Median · hour
Steady State PK Parameter--tmax, ss at Day 9
hourCohort 2(Olaparib 100 mg + Paclitaxel)
Steady State PK Parameter--tmax, ss at Day 91.48 ± 61.38
PrimarySteady State PK Parameter--CLss/F at Day 8

Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - CLss/F (PK analysis set)

Time frame:
PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Reported as:
Mean · L/h
Steady State PK Parameter--CLss/F at Day 8
L/hCohort 1Cohort 2, Olaparib Alone
Steady State PK Parameter--CLss/F at Day 87.512 ± 3.4186.745 ± 2.923

Adverse events

Collected over Includes AEs with an onset date between the first dose date in the appropriate Part and the day before first dose in Part B (for Part A only), or 30 days following the date of last dose of study medication if the subject discontinued.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Part A—0/20 (0%)11/20 (55%)
Cohort 2 Part A, Olaparib 100 mg—0/16 (0%)8/16 (50%)
Cohort 2 Part A, Olaparib 100mg in Combination With Paclitaxel—4/16 (25%)16/16 (100%)
Cohort 1 Part B—0/19 (0%)18/19 (94.7%)
Cohort 2 Part B, Olaparib 300 mg Monotherapy—0/2 (0%)2/2 (100%)
Cohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel—1/15 (6.7%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 Part ACohort 2 Part A, Olaparib 100 mgCohort 2 Part A, Olaparib 100mg in Combination With PaclitaxelCohort 1 Part BCohort 2 Part B, Olaparib 300 mg MonotherapyCohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel
NeutropeniaBlood and lymphatic system disorders0/200/163/160/190/21/15
Liver injuryHepatobiliary disorders0/200/161/160/190/20/15
Most frequent other events
Showing 10 of 93
Most frequent other events
EventCohort 1 Part ACohort 2 Part A, Olaparib 100 mgCohort 2 Part A, Olaparib 100mg in Combination With PaclitaxelCohort 1 Part BCohort 2 Part B, Olaparib 300 mg MonotherapyCohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel
LeukopeniaBlood and lymphatic system disorders3/201/1612/168/191/215/15
NeutropeniaBlood and lymphatic system disorders1/201/1611/168/191/214/15
AlopeciaSkin and subcutaneous tissue disorders0/200/169/160/190/21/15
NeurotoxicityNervous system disorders0/200/163/160/190/28/15
FatigueGeneral disorders0/202/168/165/190/22/15
AnaemiaBlood and lymphatic system disorders3/202/166/167/191/27/15
Upper respiratory tract infectionInfections and infestations0/200/161/162/190/25/15
MyalgiaMusculoskeletal and connective tissue disorders0/200/164/160/190/25/15
Alanine aminotransferase increasedInvestigations0/201/163/164/190/25/15
NauseaGastrointestinal disorders4/202/165/164/190/22/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean47.7 ± 10.4349.3 ± 9.4948.4 ± 9.92
Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Total
<50 years11920
≥50 <65 years9615
≥65 <75 years011
≥75 years000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female131528
Male718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
Chinese201636
Height
Height(cm)Cohort 1Cohort 2Total
Mean164.9 ± 6.25160.3 ± 4.81162.8 ± 6.04
Weight
Weight(kg)Cohort 1Cohort 2Total
Mean64.8 ± 10.3560.9 ± 8.7163.1 ± 9.71
Body mass index
Body mass index(kg/m2)Cohort 1Cohort 2Total
Mean23.91 ± 4.14423.78 ± 3.59923.85 ± 3.857
08

Study locations

3 sites
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100071, China
  • Research Site
    Hangzhou, 310003, China
09

References and documents

Publications

  • Yuan P, Shentu J, Xu J, Burke W, Hsu K, Learoyd M, Zhu M, Xu B. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours. Cancer Chemother Pharmacol. 2019 May;83(5):963-974. doi: 10.1007/s00280-019-03799-1. Epub 2019 Mar 18. PubMed 30887180 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Jul 2016, 13 months.

Results were first posted in Sep 2018, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
Apr 30, 2015
StartActual
Jun 10, 2015
Primary completionActual
Jul 27, 2016
CompletionActual
Apr 28, 2017
Results first posted
Sep 13, 2018
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02430311
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 30, 2015
Start date
Jun 10, 2015
Primary completion
Jul 27, 2016
Completion
Apr 28, 2017
Results posted
Sep 13, 2018
Last update
Jul 31, 2019

Study contacts

Binghe Xu, MD
principal investigator · Cancer Institute and Hospital (CIH), Chinese Academy of Medical Sciences and Peking Union Medical College
Jianming Xu, MD
principal investigator · 307 Hospital of Military Medical Sciences
Jianzhong Shentu
principal investigator · No.1 Affiliated Hospital of College of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion